Рецепт. 2018; : 525-534
Основные результаты клинического исследования безопасности лекарственного средства альгиномакс с применением дополнительного параметра оценки эндотоксемии по липополисахаридным антигенам крови
Аннотация
Результаты представленного исследования позволяют оценить переносимость лекар- ственного средства альгиномакс как преимущественно хорошую и очень хорошую, а степень его безопасности – как высокую.
Альгиномакс не оказывает воздействия на проницаемость слизистой оболочки кишечника и не увеличивает эндотоксемию липополисахаридными антигенами.
Список литературы
1. Food and Nutrition Board. Dietary reference intakes: applications in dietary assessment. Washington, DC, National Academy Press, 2001.
2. Kirch W. (ed). (2008) Encyclopedia of Public Health: Volume 1: A – H Volume 2: I – Z, pp. 669.
3. Abramson J.H. (2011) WINPEPI updated: computer programs for epidemiologists, and their teaching potential. Epidemiologic Perspectives & Innovations, 8:1.
4. Marahovskii K., Gorgun Yu., Zharskaya O., Karaseva G., Marahovskii Yu. (2015) Metod opredeleniya variantov sindroma izbitochno pronitsaemoi slizistoi obolochki kishechnika. Instruktsiya po primeneniyu [The method of determining the options of excessive permeability syndrome of the intestinal mucosa. An instruction manual]. Gosregistratsiya, no 125, pp. 1114.
5. Lanza F.L. et al. (1986) Eff ectiveness of foaming antacid in relieving induced heartburn. South. Med. J., vol. 79, pp. 327–330.
6. Nomenklatura pischevih dobavok [Food supplements nomenclature]. Commission Directive 98/86/EC.
7. Mandel K. et al. (2000) Review article: alginate-raft formulations in the treatment of heartburn and acid refl ux. Aliment. Pharmacol. Ther., vol. 14, pp. 669–690.
Recipe. 2018; : 525-534
Clinical study main results of the alginomax medicine safety using an additional parameter of endotoxemia evaluation on blood lipopolysaccharide antigens
Abstract
The results of the presented study allow evaluating the tolerability of the alginomax medicine as predominantly good and very good, and the degree of its safety as high. Alginomax does not aff ect the permeability of the intestinal mucosa and does not increase endotoxemia with lipopolysaccharide antigens.
References
1. Food and Nutrition Board. Dietary reference intakes: applications in dietary assessment. Washington, DC, National Academy Press, 2001.
2. Kirch W. (ed). (2008) Encyclopedia of Public Health: Volume 1: A – H Volume 2: I – Z, pp. 669.
3. Abramson J.H. (2011) WINPEPI updated: computer programs for epidemiologists, and their teaching potential. Epidemiologic Perspectives & Innovations, 8:1.
4. Marahovskii K., Gorgun Yu., Zharskaya O., Karaseva G., Marahovskii Yu. (2015) Metod opredeleniya variantov sindroma izbitochno pronitsaemoi slizistoi obolochki kishechnika. Instruktsiya po primeneniyu [The method of determining the options of excessive permeability syndrome of the intestinal mucosa. An instruction manual]. Gosregistratsiya, no 125, pp. 1114.
5. Lanza F.L. et al. (1986) Eff ectiveness of foaming antacid in relieving induced heartburn. South. Med. J., vol. 79, pp. 327–330.
6. Nomenklatura pischevih dobavok [Food supplements nomenclature]. Commission Directive 98/86/EC.
7. Mandel K. et al. (2000) Review article: alginate-raft formulations in the treatment of heartburn and acid refl ux. Aliment. Pharmacol. Ther., vol. 14, pp. 669–690.
